STAT+: Microbiome company Finch Therapeutics begins trading publicly, quietly shuffles one of its executives

Microbiome company Finch Therapeutics is, officially, worth about $960 million. Shares in the company began trading publicly on Friday morning.

The company’s shares were initially priced at $17; as of 11 a.m., that price had increased by 30% to nearly $22. Finch’s stock ticker is FNCH. The company announced positive topline results from a Phase 2 trial this summer for its treatment for C. difficile, a potentially fatal gut infection that often returns even after a course of antibiotics.

Continue to STAT+ to read the full story…

STAT+: Microbiome company Finch Therapeutics begins trading publicly, quietly shuffles one of its executives

Leave a Reply

Your email address will not be published. Required fields are marked *

Scroll to top